- Home
- INMB vs CNTX Comparison
INMB vs CNTX Comparison
Compare INMB & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INMB | CNTX |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | 21 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.7M | 51.5M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | INMB | CNTX |
|---|---|---|
| Price | $1.64 | $0.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $5.40 | ★ $6.60 |
| AVG Volume (30 Days) | 1.2M | ★ 3.2M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 11.85 | ★ 17.39 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $50,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 257.14 | N/A |
| 52 Week Low | $1.09 | $0.55 |
| 52 Week High | $3.24 | $3.62 |
Technical Indicators
Market Signals| Indicator | INMB | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.68 | 30.57 |
| Support Level | $1.23 | $0.55 |
| Resistance Level | $1.76 | $0.70 |
| Average True Range (ATR) | 0.17 | 0.05 |
| MACD | -0.03 | 0.05 |
| Stochastic Oscillator | 16.00 | 14.50 |
Price Performance
Historical ComparisonAbout INMB INmune Bio Inc.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.